Initial Strategies in Advanced HCC: Case 1
Initial Strategies in Advanced HCC
December 2014
- A 64-year old male positive with HCV presents to his PCP with nausea, vomiting, syncope
- ECOG=1
- Child-Pugh B
- T bilirubin 2.1; albumin 3.2; INR 1.1; no ascites, no encephalopathy; platelets 78
- CT scan revealed one 4-cm lesion in the liver
- No extrahepatic disease; no portal vein invasion
- Laboratory results: AFP=400 ng/ml
- Patient is within Milan criteria
- Bridge using TACE until liver transplantation
Hope Beyond Surgery: Optimizing Care for Cholangiocarcinoma
February 15th 2024In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.
Read More
Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC
February 6th 2024In an interview with Targeted Oncology, Bruno Sangro, MD, PhD, discussed the potential durvalumab, bevacizumab, and TACE has to set a new standard-of-care among patients with unresectable hepatocellular carcinoma.
Read More
Regorafenib Discontinuation More Likely With Poor Liver Function in Liver Cancer
January 19th 2024Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious adverse effects leading to regorafenib treatment discontinuation, researchers have found.
Read More
